AVADEL PHARMACEUTICALS PLC (AVDL)

Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Avadel Pharmaceuticals (AVDL) is a Dublin-headquartered Irish specialty pharma company with 188 employees focused on sleep disorder medicines, currently commercializing FT218 for narcolepsy after years of zero revenue. The company reported $169M in revenue for 2024 against a net loss of $49M, marking a significant commercial inflection from prior development-stage losses. Market cap stands at approximately $2.1B as of mid-July 2026.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
FT218	Phase 3	Narcolepsy

Price & technical context

3-month

+15.7%

6-month

+61.5%

12-month

+138.1%

52-wk range

$6.59–$23.56

vs 50-day MA

+0.7%

vs 200-day MA

+40.3%

Realized vol

45.8%

Max drawdown

-65.0%

Daily closes through 2026-02-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for AVDL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.